These positive earnings estimate revisions suggest that analysts are becoming more optimistic on PCYC’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Pharmacyclics could be a solid choice for investors.
Current Quarter Estimates for PCYC
In the past 30 days, 1 estimate have gone higher for Pharmacyclics while 1 has moved lower in the same time period. The trend has been pretty favorable too, with estimates increasing from a loss of 8 cents a share 30 days ago, to earnings of 18 cents today, a significant move upward.
Current Year Estimates for PCYC
Meanwhile, Pharmacyclics’s current year figures are also looking quite promising, with 2 estimates moving higher in the past month, compared to 1 lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 40 cents per share 30 days ago to a loss of 28 cents per share today, an improvement of 30.0 %.
Bottom Line
The stock has also started to move higher lately, adding 7.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment